Nordicus Partners Corp (NORD)

[e-ore]

My opinion is that after this news (that I missed) we'll see a jump in product sales. Chronoflex C is an ASNB product. Finally the Powerwand may find some traction in the marketplace.

January 25, 2017
Access Scientific, LLC, Awarded Intalere Choice®
Agreement for POWERWAND™ Line of Catheters
SAN DIEGO – Access Scientific, a privately held medical device manufacturer of
the “evidence based, best in class” POWERWAND catheters, was awarded an
agreement with Intalere as a supplier of its valued Intalere Choice program.
Intalere is a leading group purchasing and total cost management organization
that serves 3,716 acute care facilities nationwide along with 37,356 clinics and
11,598 long term care facilities. For premium products, Intralere offers Intalere
Choice to provide their members the highest quality medical products in growing
sectors such as vascular access. The agreement became effective Dec. 1, 2016.
The agreement provides Intalere Choice member facilities access to Access
Scientific’s proprietary line of POWERWAND catheters, which have demonstrated
unparalleled performance in clinical outcomes:
? 3Fr, 4Fr and 5Fr (16Ga, 17Ga and 19Ga) catheter offering
? Reduce overall central lines and central line days
? 12,000 catheter-days with no bloodstream infection
? Highest flow rates
? Excellent blood drawability
? Cost savings (clinical and material)
The POWERWAND line of catheters has been proven to help facilities reduce
central line days and CLABSIs while improving quality care at a lower cost, all of
which are core to value-based purchasing.
“The Access team looks forward to partnering with Intalere and their members to
improve patient care and lower the overall cost of care through implementation
of our evidence-based Powerwand products and processes,” said Phil Royston,
President of Access Scientific.
About Access Scientific, LLC
Access Scientific is dedicated to the development and commercialization of
breakthrough, proprietary devices that make vascular access safer for patients
and reduce the cost of care. The company pioneered the power-injectable midline
market with the POWERWAND™. Made of proprietary ChronoFlex™ C, the
POWERWAND midline has been the proven, evidence based, best-in-class, with
over 12,000 catheter-days of published scientific data attesting to the lowest
complication rate and highest completion-of-therapy rate of any vascular access
device ever studied. The POWERWAND offers a unique approach to reducing
hospital-acquired infections. Visit www.accessscientific.com to learn more.
– END –

A more recent study shows 20,000 days of results.

"March 14, 2017
New Study Pushes POWERWAND Midline IV Catheter
to Over 20,000 Catheter Days with Zero BSIs"

http://3g033q44pk4o4eo9td3bwjsx.wpengine.netdna-cdn.com/wp-content/uploads/20000-Catheter-Days.pdf

"BSI" stands for bloodstream infections. They are acquired in the hospital and insurance and medicare don't pay for them. From another recent study which showed no Powerwand bloodstream infections:

"Contrast these outcomes with the predictable consequences our patients would have had if PICCs had been mandated for all vancomycin administrations. At the low end of the reported PICC-associated bloodstream infection rate, approximately 16 patients in our cohort would have had catheter-associated bloodstream infections, and 1 or 2 of these patients quite possibly would have died. The unreimbursable cost of treating 16 patients with CLABSI would have been $896,000.23 Compare this with the actual hard-cost savings of $97,740 (1086 patients × $90 savings per procedure) that resulted from using the study midline catheter (the Powerwand) instead of a PICC for vancomycin administration."

http://www.avajournal.com/article/S1552-8855(16)30127-1/fulltext

Next filing is the annual report coming out in mid-July. I'm looking forward to it and will add some at these prices.